Amneal rises after US FDA nod for generic asthma inhaler

Shares of drugmaker Amneal Pharmaceuticals AMRX.O rise 1.2% to $12.45 premarket

Co says U.S. FDA approved its generic version of a widely used asthma drug, albuterol sulfate inhalation aerosol

Approval comes after FDA cleared co's generic version of Teva's TEVA.TA QVAR inhaler for asthma - AMRX

Co says both approvals mark progress in complex respiratory drug market

Up to last close, stock up ~55% YTD